Eyepoint Pharmaceuticals Inc
$ 14.19
-0.28%
10 Apr - close price
- Market Cap 1,183,899,000 USD
- Current Price $ 14.19
- High / Low $ 14.36 / 13.90
- Stock P/E N/A
- Book Value 3.70
- EPS -3.17
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -0.72 %
- 52 Week High 19.11
- 52 Week Low 5.14
About
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$37.42
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-03-05 | 2024-11-08 | 2024-08-07 | 2024-05-08 | 2024-03-07 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.81 | -0.85 | -0.85 | -0.65 | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 | -0.33 | -0.61 | -0.56 |
| Estimated EPS | -0.7477 | -0.77 | -0.81 | -0.41 | -0.4765 | -0.55 | -0.52 | -0.42 | -0.49 | -0.51 | 0.6 | -0.68 |
| Surprise | -0.0623 | -0.08 | -0.04 | -0.24 | -0.1635 | 0.01 | -0.06 | -0.13 | 0.16 | 0.18 | -1.21 | 0.12 |
| Surprise Percentage | -8.3322% | -10.3896% | -4.9383% | -58.5366% | -34.3127% | 1.8182% | -11.5385% | -30.9524% | 32.6531% | 35.2941% | -201.6667% | 17.6471% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.79 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EYPT
2026-04-09 21:09:22
This article analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) using predictive AI, highlighting a strong near-term sentiment shifting to a long-term positive bias. It presents an exceptional 77.3:1 risk-reward setup targeting a 22.7% gain with minimal risk and outlines specific position, momentum, and risk-hedging trading strategies developed by AI models for different risk profiles.
2026-04-07 06:09:37
Eyepoint Pharmaceuticals (NASDAQ:EYPT) has received a "Buy" consensus recommendation from eight brokerages, with an average 12-month price target of $32.20. Despite recent weak quarterly results and negative profitability metrics, several firms, including Citigroup and HC Wainwright, have raised their price targets. Institutional investors hold a significant 99.41% stake in the company.
2026-04-06 17:40:23
Eyepoint Pharmaceuticals (NASDAQ:EYPT) saw its stock price fall by 3.7% to $12.90 on Monday, with a significant 94% drop in trading volume compared to its average. Despite weak company fundamentals, including missed quarterly earnings and revenue expectations, analysts largely maintain a "Buy" rating with a consensus target price of $32.20. Institutional investors have been actively adjusting their positions, with several major firms increasing their stakes in the biopharmaceutical company.
2026-04-06 07:39:56
Aberdeen Group plc significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 101.6% in the fourth quarter, bringing its total holdings to 1,605,984 shares valued at approximately $29.34 million. This move highlights strong institutional interest, with 99.41% of the company's shares owned by institutional investors. Despite recent EPS misses and negative profitability, the stock maintains an average "Buy" rating from analysts with a mean target price of $32.20.
2026-03-31 00:40:45
This entry appears to be a stub or a link to a financial platform. It indicates a focus on providing current stock price quotes and charts for EyePoint Inc (EYPT). The reference to "Online Trading with Smart Investment App | Capital.com" suggests that Capital.com is the source or platform for this information.
2026-03-29 19:58:00
Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) is showing weak near and mid-term sentiment, posing a challenge to its long-term positive outlook. The analysis from Stock Traders Daily's Quantitative Research Desk highlights elevated downside risk due to a lack of additional long-term support signals. Three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—have been generated by AI models, tailored to different risk profiles and holding periods, with specific entry, target, and stop-loss levels.
